The 340B Drug Pricing Program enables eligible healthcare organizations to purchase outpatient drugs at discounted prices. However, manufacturers face significant financial losses due to duplicate discounts, where covered entities receive both a 340B discount and a payer rebate for the same drug. Scrubbing for 340B duplicate discounts involves reviewing claims data to identify and prevent such occurrences. Challenges include ensuring compliance, maintaining auditable records, and addressing drug diversion. Best practices include robust data management, eligibility verification, and compliance monitoring to improve program integrity.

Join for free to read